D. Boral Capital Reiterates “Buy” Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $36.00 price target on the biopharmaceutical company’s stock. D. Boral Capital’s price target suggests a potential upside of 349.44% from the stock’s previous close.

A number of other research firms have also commented on OMER. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Friday, January 17th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Performance

OMER stock opened at $8.01 on Tuesday. The stock’s 50 day moving average price is $8.61 and its 200 day moving average price is $7.61. The firm has a market cap of $464.18 million, a P/E ratio of -3.47 and a beta of 2.03. Omeros has a 1 year low of $2.97 and a 1 year high of $13.60.

Institutional Trading of Omeros

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. Truvestments Capital LLC lifted its holdings in shares of Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,669 shares during the period. Tower Research Capital LLC TRC raised its stake in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares during the period. Quantbot Technologies LP purchased a new position in Omeros during the fourth quarter worth approximately $46,000. BNP Paribas Financial Markets boosted its holdings in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 7,016 shares during the last quarter. Finally, Picton Mahoney Asset Management grew its stake in shares of Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 4,404 shares during the period. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.